8 November 2022FeaturesMuireann Bolger

Sea change: a Q&A with Kathi Vidal

You have always been a proponent of diversity and inclusion. What drove you to make that an area of focus?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Careers

White & Case life sciences co-leader moves firms

2 September 2026 The senior transactions specialist brings experience advising pharmaceutical, biotechnology and technology companies on strategic alliances, licensing, M&A and cross-border transactions.

Careers

‘Busiest’ US district patent judge swaps bench for private practice

2 September 2026 One of the country's most prominent patent judges has joined A&O Shearman after nearly eight years on the federal bench.

Biotech

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.

More features

Former USPTO acting director takes the helm at C4IP

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

The UPC plugs another gap in its procedural rulebook

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Exclusive: ‘Cultural differences are an asset’ at the UPC

Sea change: a Q&A with Kathi Vidal

More on this story

Editor's picks

Editor's picks

More features